GU Cancers 2019 | VERU-111: a potential new oral agent for mCRPC

Many of the chemotherapy drugs currently available for metastatic castration-resistant prostate cancer (mCRPC) are administered through an intravenous (IV) line and target β-tubulin. Robert Getzenberg, PhD, of the NSU MD, Fort Lauderdale, FL, presents VERU-111, a novel oral small molecule that targets both the α and β tubulin subunits of microtubules. Speaking at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA, Prof Getzenberg talks about the Phase I study (NCT03752099) evaluating the safety and tolerability of this novel agent in mCRPC.